- Report
- August 2023
- 51 Pages
France
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Turkey
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Israel
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Colombia
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Italy
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
South Korea
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
India
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Saudi Arabia
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
South Africa
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Spain
From €527EUR$600USD£460GBP
- Report
- August 2023
- 51 Pages
Brazil
From €527EUR$600USD£460GBP
- Report
- December 2024
- 150 Pages
Global
From €2951EUR$3,358USD£2,577GBP
€3472EUR$3,950USD£3,031GBP
- Report
- December 2024
- 150 Pages
Global
From €2951EUR$3,358USD£2,577GBP
€3472EUR$3,950USD£3,031GBP
- Report
- December 2024
- 150 Pages
Global
From €2951EUR$3,358USD£2,577GBP
€3472EUR$3,950USD£3,031GBP
- Report
- July 2024
- 151 Pages
Global
From €3175EUR$3,613USD£2,772GBP
€3735EUR$4,250USD£3,262GBP
- Report
- October 2025
- 150 Pages
China
From €3384EUR$3,850USD£2,955GBP
- Report
- November 2024
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
€4263EUR$4,850USD£3,722GBP
- Report
- November 2024
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
€4263EUR$4,850USD£3,722GBP
- Report
- September 2024
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
€4263EUR$4,850USD£3,722GBP
- Report
- January 2024
- 150 Pages
Global
From €3384EUR$3,850USD£2,955GBP
€4263EUR$4,850USD£3,722GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more